RecruitingPhase 2NCT06162013

The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism

Studying Atypical progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Haukeland University Hospital
Principal Investigator
Charalampos Tzoulis, MD, PhD
Haukeland University Hospital
Intervention
Nicotinamide Riboside(dietary_supplement)
Enrollment
330 enrolled
Eligibility
30-85 years · All sexes
Timeline
2024 – 2028

Study locations (3)

Collaborators

Oslo University Hospital · Akershus Universitetssykehus HF · Vestre Viken Hospital Trust · Sykehuset Ostfold · Nevro Arendal AS · Helse Forde · Helse Fonna · Universitetssykehuset Nord Norge HF · Helse Møre og Romsdal HF · Nordlandssykehuset HF · Elysium Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06162013 on ClinicalTrials.gov

Other trials for Atypical progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Atypical progressive supranuclear palsy syndrome →

← Back to all trials